ArticleCancer1986
Intermittent endocrine therapy for advanced prostate cancer.
Article in Cancer, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2014Pooled it
- Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.BMC urology · 2014Pooled it
- Intermittent versus continuous androgen suppression for prostatic cancer.The Cochrane database of systematic reviews · 2007Pooled it
- Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Trial
- Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Intermittent androgen suppression for rising PSA level after radiotherapy.The New England journal of medicine · 2012 · on this mapTrial
- The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.Prostate cancer and prostatic diseases · 2005Trial
- Single-threshold-guided adaptive cancer therapy with partial-cycle treatment: A mechanistic and reinforcement learning analysis.PLoS computational biology · 2026Article
- A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.Journal of clinical medicine · 2023Article
- Genitourinary tumors.Journal of surgical oncology · 2022Review
- Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer.Bulletin of mathematical biology · 2021Article
- Group Behavior and Emergence of Cancer Drug Resistance.Trends in cancer · 2021Review
- Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.Nature reviews. Urology · 2020Review
- The history of intermittent androgen deprivation therapy - A Canadian story.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.Asian journal of urology · 2017Review
- Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer.Clujul medical (1957) · 2016Article
- International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.ESMO open · 2016Article
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Article
- 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.The Journal of urology · 2015Article
- The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.Current urology reports · 2015Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Twenty patients with advanced prostate cancer have been treated with an intermittent endocrine therapy schedule. Hormone therapy (diethylstilbestrol in 19 patients and flutamide in 1 patient) was administered until a clinical response was clearly demonstrated and then it was withheld until symptoms recurred. Prior to treatment 17 of 20 patients had bone pain and positive radionuclide scans, two had asymptomatic pulmonary metastases, and one had symptomatic localized disease. Duration of endocrine therapy prior to withdrawal of all treatment ranged 2 to 70 months (median, 10 months). Disease progression occurred 1 to 24 months (median, 8 months) after interruption of therapy. All patients who relapsed had a rapid clinical response following resumption of endocrine therapy. Nine of ten patients rendered impotent by endocrine therapy resumed sexual activity within 3 months of stopping treatment. This data indicates that satisfactory palliation of advanced prostatic cancer can be achieved in selected patients using intermittent endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.